Abstract:The activation of cyclic GMP–AMP synthase (cGAS) by double-stranded DNA is implicated in the pathogenesis of many hyperinflammatory and autoimmune diseases, and the cGAS-targeting small molecule has emerged as a novel therapeutic strategy for treating these diseases. However, the currently reported cGAS inhibitors are far beyond maturity, barely demonstrating in vivo efficacy. Inspired by the structural novelty of compound 5 (G140), we conducted a structural optimization on both its side chain and the central tricyclic core, leading to several subseries of compounds, including those unexpectedly cyclized complex ones. Compound 25 bearing an N-glycylglycinoyl side chain was identified as the most potent one with cellular IC50 values of 1.38 and 11.4 μM for h- and m-cGAS, respectively. Mechanistic studies confirmed its direct targeting of cGAS. Further, compound 25 showed superior in vivo anti-inflammatory effects in the lipopolysaccharide-induced mouse model. The encouraging result of compound 25 provides solid evidence for further pursuit of cGAS-targeting inhibitors as a new anti-inflammatory treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00398?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00398</a>.Proposed mechanism for the formation of compounds 53 and 54, variable-temperature NMR spectra of compound 20, 1H and 13C spectra of all new compounds, and X-ray crystal structure data for compounds 47, 53, 57, 63, and 65 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_002.csv">CSV</a>)Crystallographic data of compound 47 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_003.cif">CIF</a>)Crystallographic data of compound 53 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_004.cif">CIF</a>)Crystallographic data of compound 57 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_005.cif">CIF</a>)Crystallographic data of compound 63 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_006.cif">CIF</a>)Crystallographic data of compound 65 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00398/suppl_file/jm1c00398_si_007.cif">CIF</a>)This article has not yet been cited by other publications.

Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases

Discovery of Small Molecule Cyclic GMP-AMP Synthase Inhibitors.

Design, Synthesis, and Pharmacological Evaluation of Spiro[carbazole-3,3'-pyrrolidine] Derivatives as cGAS Inhibitors for Treatment of Acute Lung Injury

Development of Human Cgas-Specific Small-Molecule Inhibitors for Repression of Dsdna-Triggered Interferon Expression

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

Discovery and characterization of a novel cGAS covalent inhibitor for the treatment of inflammatory bowel disease

Synthesis and Pharmacological Evaluation of Tetrahydro-γ-carboline Derivatives as Potent Anti-inflammatory Agents Targeting Cyclic GMP–AMP Synthase

Small molecules targeting cGAS-STING pathway for autoimmune disease

Agonists and Inhibitors of the Cgas-Sting Pathway

The Potential of NOD-like Receptor Protein 3 Inflammasome Inhibitors in the Treatments of Diseases

Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP

Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: Biologic function, mechanisms and clinical prospection

Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases

Development of cyclopeptide inhibitors of cGAS targeting protein-DNA interaction and phase separation

Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases

Cyclopeptide Inhibitors Target the N‐Terminal Tail of STING and Alleviate Autoinflammation

Novel Azepino[4,5- b ]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases

Inhibiting the cGAS-STING Pathway in Ulcerative Colitis with Programmable Micelles

Discovery of novel cGAS inhibitors based on natural flavonoids

The cGAS–STING pathway as a therapeutic target in inflammatory diseases

Harnessing cGAS-STING axis for therapeutic benefits in systemic lupus erythematosus